Get the Stockscreener App
18.23
0.05%
0.01
After Hours:
18.23
Overview
News
Price History
Option Chain
Financials
Why SLP Down?
Discussions
Forecast
Stock Split
Dividend History
Simulations Plus Inc stock is traded at $18.23, with a volume of 153.44K.
It is up +0.05% in the last 24 hours and up +7.24% over the past month.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
See More
Previous Close:
$18.22
Open:
$18.19
24h Volume:
153.44K
Relative Volume:
0.39
Market Cap:
$367.24M
Revenue:
$66.98M
Net Income/Loss:
$9.65M
P/E Ratio:
37.98
EPS:
0.48
Net Cash Flow:
$10.19M
1W Performance:
-4.95%
1M Performance:
+7.24%
6M Performance:
+4.47%
1Y Performance:
-34.64%
1-Day Range:
$18.01
$18.37
1-Week Range:
$18.01
$19.31
52-Week Range:
$12.39
$37.66
Simulations Plus Inc Stock (SLP) Company Profile
Name
Simulations Plus Inc
Sector
Industry
Phone
661-723-7723
Address
800 PARK OFFICES DRIVE, SUITE 401, RESEARCH TRIANGLE PARK, CA
Compare SLP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLP
Simulations Plus Inc
|
18.23 | 367.03M | 66.98M | 9.65M | 10.19M | 0.48 |
|
VEEV
Veeva Systems Inc
|
223.23 | 36.93B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
59.05 | 10.74B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
44.28 | 8.39B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
91.61 | 7.90B | 1.15B | 96.70M | -161.99M | 1.09 |
|
BTSG
Brightspring Health Services Inc
|
37.45 | 6.79B | 11.99B | 24.18M | 234.31M | 0.2956 |
Simulations Plus Inc Stock (SLP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-30-25 | Initiated | TD Cowen | Hold |
| Jul-15-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Nov-15-24 | Initiated | Stephens | Overweight |
| Jul-29-24 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-16-24 | Initiated | JMP Securities | Mkt Perform |
| Jun-28-24 | Initiated | William Blair | Outperform |
| May-09-23 | Initiated | BTIG Research | Buy |
| Oct-26-21 | Upgrade | Craig Hallum | Hold → Buy |
| Jan-12-21 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-16-20 | Initiated | Raymond James | Outperform |
| Sep-08-20 | Initiated | Oppenheimer | Outperform |
| Jan-06-20 | Initiated | Craig Hallum | Buy |
View All
Simulations Plus Inc Stock (SLP) Latest News
Signal Recap: Will Simulations Plus Inc stock outperform Nasdaq indexJuly 2025 Chart Watch & AI Optimized Trade Strategies - moha.gov.vn
Simulations Plus (NASDAQ: SLP) details 2026 meeting, auditor and equity plan votes - Stock Titan
Simulations Plus (FRA:SD3) Intrinsic Value: Projected FCF : €10.77 (As of Dec. 27, 2025) - GuruFocus
Guidance Update: Is PCGPRH stock overvalued by current metricsJuly 2025 PreEarnings & Low Volatility Stock Suggestions - moha.gov.vn
Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Viridian Therapeutics (VRDN) - The Globe and Mail
Simulations Plus, Inc. (NASDAQ:SLP) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
(SLP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Simulations Plus (SLP) Highlights FDA Alignment as Citizens Maintains Market Perform - Insider Monkey
Will Simulations Plus Inc. stock benefit from green energy trendsJuly 2025 Review & Risk Managed Investment Entry Signals - Улправда
Diluted shares outstanding of Simulations Plus, Inc. – FWB:SD3 - TradingView — Track All Markets
Current ratio of Simulations Plus, Inc. – FWB:SD3 - TradingView — Track All Markets
Can Simulations Plus Inc. stock deliver strong Q4 earnings2025 Historical Comparison & High Return Stock Watch Alerts - DonanımHaber
Will Simulations Plus Inc. stock attract more institutional investorsQuarterly Profit Report & Weekly Top Gainers Trade List - DonanımHaber
Trading Recap: Will Simulations Plus Inc. stock benefit from green energy trendsMarket Sentiment Report & Fast Gaining Stock Reports - Улправда
Simulations Plus (SLP) Upgraded to Strong Buy: Here's What You Should Know - sharewise.com
Will Simulations Plus Inc. stock maintain growth story2025 Institutional Moves & Daily Market Momentum Tracking - Улправда
Simulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug Development - 01net
SLP Downgraded to Neutral by BTIG Analyst David Larsen | SLP Sto - GuruFocus
Will Simulations Plus Inc. stock rally after Fed decisionsTake Profit & Weekly Watchlist for Hot Stocks - Улправда
Simulations Plus in Minus Category on Word of Investor Day in January - Barchart.com
Simulations Plus Announces First Quarter Fiscal Year 2026 Earnings and Conference Call Date - 01net
Press Release: Simulations Plus Announces First Quarter Fiscal Year 2026 Earnings and Conference Call Date - 富途牛牛
Simulations Plus Reports Q4 2025 Financial Results - MSN
When Should You Buy Simulations Plus, Inc. (NASDAQ:SLP)? - Yahoo Finance
Ranger Investment Management L.P. Trims Stake in Simulations Plus, Inc. $SLP - MarketBeat
Simulations Plus challenges PKanalix in software efficiency - Traders Union
Simulations Plus (NASDAQ:SLP) Updates FY 2026 Earnings Guidance - MarketBeat
Simulations Plus Positioned to Capitalize on FDA's Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed Solutions - marketscreener.com
Russell Investments Group Ltd. Sells 112,542 Shares of Simulations Plus, Inc. $SLP - MarketBeat
Simulations Plus Positioned to Capitalize on FDA’s Streamlined Nonclinical Safety Guidance with Adva - pharmiweb.com
Simulations Plus responds to FDA draft guidance on antibody testing - Investing.com
Simulations Plus responds to FDA draft guidance on antibody testing By Investing.com - Investing.com South Africa
Simulations Plus Positioned to Capitalize on FDA’s Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed Solutions - The AI Journal
Simulations Plus: Solid Platform, Soft Outlook (Rating Upgrade) - Seeking Alpha
With Simulations Plus Stock Surging, Have You Considered The Downside? - Trefis
Simulations Plus amends executive employment agreements with new compensation terms - Investing.com
Simulations Plus (NASDAQ: SLP) sets new executive salaries, bonuses and option targets - Stock Titan
Kennedy Capital Management LLC Sells 84,846 Shares of Simulations Plus, Inc. $SLP - MarketBeat
Simulations Plus urges attendance for PBPK regulatory webinar - Traders Union
How sustainable is Simulations Plus Inc. stock dividend payoutMarket Risk Analysis & Weekly High Potential Stock Alerts - Newser
Why Shares of Simulations Plus Soared This Week - The Globe and Mail
Why shares of Simulations Plus soared this week - MSN
Simulations Plus (NASDAQ:SLP) Shareholders Are up 18% This Past Week, but Still in the Red Over the Last Five Years - 富途牛牛
William Blair Raises Earnings Estimates for Simulations Plus - MarketBeat
Why Simulations Plus Inc. stock could benefit from AI revolution2025 Trading Volume Trends & Fast Moving Market Watchlists - Newser
Simulations Plus Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Simulations Plus' Q4 Earnings & Sales Meet Estimates, Fall Y/Y - sharewise.com
Why Simulations Plus Stock Was Soaring Today - Finviz
Simulations Plus: Buying On Long-Term Silico Drug-Development - Seeking Alpha
Simulations Plus Inc Stock (SLP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.12%
3.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):